Annual cocktail party with live band, dancing and more to benefit Dana-Farber Cancer Institute
BOSTON – Grab your ties, cocktail dresses and dancing shoes for Fall Formal, held from 9:30 p.m. – 1 a.m. on Saturday, November 12 at The Castle at Park Plaza. This annual event brings together the young professional community in Boston for an unforgettable night to support patient care and cancer research at Dana-Farber Cancer Institute.
The evening’s festivities include a hosted bar, hors d’oeuvres, a live band, dancing, opportunity drawing, silent auction and more. Cocktail attire is encouraged. Tickets start at $105 and should be purchased in advance, as this event is expected to sell out for the third year in a row. Sponsorship opportunities are still available.
Since its inception in 2014, Fall Formal, run by a local, all-volunteer committee, has raised over $175,000 for Dana-Farber Cancer Institute.
For more information, including sponsorship and ticket details, please visit: www.fallformal.com
About Dana-Farber Cancer Institute
From achieving the first remissions in cancer with chemotherapy in 1948, to developing the very latest new therapies, Dana-Farber Cancer Institute is one of the world’s leading centers of cancer research and treatment. It is the only center ranked in the top 4 of U.S. News and World Report’s Best Hospitals for both adult and pediatric cancer care.
Dana-Farber sits at the center of a wide range of collaborative efforts to reduce the burden of cancer through scientific inquiry, clinical care, education, community engagement, and advocacy. Dana-Farber/Brigham and Women’s Cancer Center provides the latest in cancer care for adults; Dana-Farber/Boston Children's Cancer and Blood Disorders Center for children. The Dana-Farber/Harvard Cancer Center unites the cancer research efforts of five Harvard academic medical centers and two graduate schools, while Dana-Farber Community Cancer Care provides high quality cancer treatment in communities outside Boston’s Longwood Medical Area.
Dana-Farber is dedicated to a unique 50/50 balance between cancer research and care, and much of the Institute’s work is dedicated to translating the results of its discovery into new treatments for patients locally, and around the world.